Placebo News and Research

RSS

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Amgen today announced a neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. The collaboration accelerates Amgen's potential entry into Alzheimer's disease by teaming up with Novartis on a differentiated and genetically validated Alzheimer's disease program directed at genetically predisposed individuals at risk of developing Alzheimer's disease.

2 Sep 2015

Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Ticagrelor administered in the ambulance reduces ischaemic events 24 hours after primary percutaneous coronary intervention (PCI), according to findings from the ATLANTIC-H24 study presented for the first time today at ESC Congress.

1 Sep 2015

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada.

1 Sep 2015

DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

Fatal bleeding is rare with extended dual antiplatelet therapy, according to a secondary analysis of the DAPT Study presented for the first time today at ESC Congress. Bleeding-related mortality accounted for a minority of deaths in patients treated with dual antiplatelet therapy beyond one year.

1 Sep 2015

$Gene transfer therapy not beneficial for heart failure patients with reduced ejection fraction$

Gene transfer therapy not beneficial for heart failure patients with reduced ejection fraction

Gene transfer therapy aimed at correcting an enzyme abnormality involved in myocardial contraction and relaxation did not improve outcomes in heart failure patients with reduced ejection fraction, results of the CUPID 2 study show.

1 Sep 2015

BCM injection does not prevent cardiac remodeling in heart attack patients

An investigational material known Bioabsorbable Cardiac Matrix (BCM) that is injected through the coronary artery to prevent cardiac remodelling in heart attack patients had no significant effect compared to a saline placebo, according to results of the PRESERVATION I trial.

1 Sep 2015

Benznidazole has significant antiparasitic activity, but does not reduce progression of Chagas cardiomyopathy

A 40 to 80 day treatment with the antiparasitic medication benznidazole significantly reduced parasite activity in the blood, but not progression, of serious heart problems over a 5-year period among patients with established Chagas disease (CD) cardiomyopathy, results of the BENEFIT trial show.

1 Sep 2015

Multiple HIV-1 variants at the beginning of infection impact viral load setpoints

HIV-1 infection with multiple founder variants points to poorer clinical outcomes than infection with a single variant, according to a paper published today in the journal Nature Medicine.

1 Sep 2015

New way to understand how transcranial magnetic stimulation can give relief for severe depression

A group of UK scientists have found a way of understanding how transcranial magnetic stimulation (TMS) can give relief to severely depressed patients. TMS is used as an alternative to Electro-Convulsive Therapy (ECT), but it is not known how it achieves its therapeutic effect. Understanding how it works may open the door to better, more targeted treatment for depression and other conditions.

31 Aug 2015

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942.

31 Aug 2015

TECOS analysis shows sitagliptin safe and effective in patients with type-2 diabetes, cardiovascular disease

Patients with type-2 diabetes and cardiovascular disease can safely take the antihyperglycemic drug sitagliptin without an increased risk of cardiovascular complications - even if they have a history of heart failure - a new analysis of the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) study shows.

31 Aug 2015

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial.

31 Aug 2015

Cyclosporine drug does not improve outcomes in STEMI patients receiving PCI

The immunosuppressant drug cyclosporine did not improve clinical outcomes compared to placebo in patients receiving percutaneous coronary intervention (PCI) for the more severe form of heart attack known as ST-segment elevation myocardial infarction (STEMI).

31 Aug 2015

Single dose of cocaine can impair ability to recognise negative emotions

A single dose of cocaine can interfere with the ability to recognise negative emotions, according to new research presented at the ECNP conference in Amsterdam.

31 Aug 2015

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2015 and updates on its drug development programs.

28 Aug 2015

Obesity raises Lynch syndrome CRC risk

Obesity increases the risk of colorectal cancer in patients with Lynch syndrome, research indicates, but daily aspirin use may combat this excess risk.

27 Aug 2015

UiO researchers test new nasal spray device for treating mental illness

Researchers at the University of Oslo have tested a new device for delivering hormone treatments for mental illness through the nose. This method was found to deliver medicine to the brain with few side effects.

27 Aug 2015

Novartis receives FDA approval for expanded use of Promacta for younger children with rare blood disorder

Novartis announced today that the US Food and Drug Administration has approved an expanded use for Promacta to include children 1 year of age and older with chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

26 Aug 2015

Omega-3 supplements fail to slow cognitive decline in older persons, NIH clinical study shows

While some research suggests that a diet high in omega-3 fatty acids can protect brain health, a large clinical trial by researchers at the National Institutes of Health found that omega-3 supplements did not slow cognitive decline in older persons. With 4,000 patients followed over a five-year period, the study is one of the largest and longest of its kind.

26 Aug 2015

Clementia expands enrollment to include children with FOP in ongoing Phase 2 clinical trial

Clementia Pharmaceuticals, Inc. today announced the initiation of enrollment of children as young as 6 years old in the company's ongoing Phase 2 study of palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP).

26 Aug 2015

Placebo News and Research

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

Gene transfer therapy not beneficial for heart failure patients with reduced ejection fraction

BCM injection does not prevent cardiac remodeling in heart attack patients

Benznidazole has significant antiparasitic activity, but does not reduce progression of Chagas cardiomyopathy

Multiple HIV-1 variants at the beginning of infection impact viral load setpoints

New way to understand how transcranial magnetic stimulation can give relief for severe depression

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

TECOS analysis shows sitagliptin safe and effective in patients with type-2 diabetes, cardiovascular disease

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

Cyclosporine drug does not improve outcomes in STEMI patients receiving PCI

Single dose of cocaine can impair ability to recognise negative emotions

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Obesity raises Lynch syndrome CRC risk

UiO researchers test new nasal spray device for treating mental illness

Novartis receives FDA approval for expanded use of Promacta for younger children with rare blood disorder

Omega-3 supplements fail to slow cognitive decline in older persons, NIH clinical study shows

Clementia expands enrollment to include children with FOP in ongoing Phase 2 clinical trial

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News